BNB Plus (BNBX) Registration Filing summary

Company overview and business model

• Operates as a digital asset treasury company, focusing on accumulating and managing BNB, the native cryptocurrency of the Binance blockchain, as its primary reserve asset through staking, liquidity provision, and DeFi strategies.

• Commercializes proprietary nucleic acid production solutions for biopharmaceutical and diagnostics markets via its LineaRx subsidiary, enabling cell-free DNA and RNA manufacturing for advanced therapeutics and diagnostics.

• Recent corporate developments include the formation of subsidiaries Build & Build, LLC and BNBX Ltd. to house cryptocurrency assets, and a name and ticker change to reflect the new strategic focus.

Financial performance and metrics

• Raised $26.7 million in gross proceeds from private placements in October 2025, with potential for up to $30.8 million more from warrant exercises, totaling up to $57.6 million.

• As of December 15, 2025, holds approximately 18,830 BNB tokens through direct holdings and OBNB Trust Units.

• Sold 10,759 shares via an at-the-market offering, raising $31,791 in net proceeds as of December 15, 2025.

Use of proceeds and capital allocation

• Proceeds from warrant exercises will be used primarily for the continued development and implementation of the BNB-focused treasury strategy, as well as for working capital and general corporate purposes.

• No proceeds will be received from the resale of shares by selling stockholders.